Microsoft PowerPoint - Roche IR Event EULAR Final.ppt
Microsoft PowerPoint - Roche IR Event EULAR Final.ppt
Microsoft PowerPoint - Roche IR Event EULAR Final.ppt
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Efficacy with repeat treatment<br />
In DMARD and TNF inadequate responders<br />
1 or more courses<br />
of RTX<br />
2 or more courses<br />
of RTX<br />
3 or more courses > 3 courses of RTX No. patients with > 24<br />
of RTX<br />
(1 g x 2) + MTX<br />
weeks<br />
with an <strong>IR</strong> to TNF inhibitors * FU post 3 rd course<br />
210<br />
97<br />
1053<br />
68<br />
400<br />
94<br />
57<br />
Patients receiving > 3 courses of<br />
rituximab (1 g x 2) + MTX with an <strong>IR</strong><br />
to DMARDs *<br />
*Patients who had initially received rituximab (0.5 g x 2) + MTX or rituximab monotherapy were excluded from the efficacy analyses<br />
41
Change language